ABSTRACTAs long as breast cancer (BC) stays under immunosurveillance, it can be controlled by treatments eliciting anticancer immune responses. However, once BC escapes immunosurveillance, it becomes therapeutically uncontrollable. A paper in the Journal for ImmunoTherapy of Cancer describes a new hormone receptor-positive BC cell line generating incurable tumors in C57BL/6 mice
International audienceObjectives. To better understand how immune responses may be harnessed against...
ABSTRACTPredisposition to breast and extrauterine Müllerian carcinomas in BRCA1 mutation carriers is...
In recent years, immune manipulation for cancer treatment, including breast cancer, has been increas...
Background: Progress in breast cancer (BC) research relies on the availability of suitable cell line...
The capacity of immune system to control and shape cancer, that is, cancer immunoediting, is the res...
Breast carcinoma is one of the leading causes of deaths among women worldwide. The immune response i...
Current preclinical models to investigate human HR + breast cancer progression and response to immun...
The limit therapeutic effect of traditional therapeutic approaches against breast cancer (BC) compel...
Cancer immunosurveillance is a process that results from activity of recognition and destruction of ...
Estrogen receptor-positive (ER+) tumors account for 70-80% of all breast cancer (BC) cases and are c...
Immunotherapeutics that target the immune responses in mammary tumors are a promising alternative tr...
Evidence of cancer immunosurveillance and immunoediting processes has been primarily demonstrated in...
Cancer vaccines serve as a promising clinical immunotherapeutic strategy that help to trigger an eff...
Breast cancer recurrence is the primary cause of mortality in breast cancer, and although advances h...
Vaccines against human breast cancer are an unfulfilled promise. Despite decades of promising precl...
International audienceObjectives. To better understand how immune responses may be harnessed against...
ABSTRACTPredisposition to breast and extrauterine Müllerian carcinomas in BRCA1 mutation carriers is...
In recent years, immune manipulation for cancer treatment, including breast cancer, has been increas...
Background: Progress in breast cancer (BC) research relies on the availability of suitable cell line...
The capacity of immune system to control and shape cancer, that is, cancer immunoediting, is the res...
Breast carcinoma is one of the leading causes of deaths among women worldwide. The immune response i...
Current preclinical models to investigate human HR + breast cancer progression and response to immun...
The limit therapeutic effect of traditional therapeutic approaches against breast cancer (BC) compel...
Cancer immunosurveillance is a process that results from activity of recognition and destruction of ...
Estrogen receptor-positive (ER+) tumors account for 70-80% of all breast cancer (BC) cases and are c...
Immunotherapeutics that target the immune responses in mammary tumors are a promising alternative tr...
Evidence of cancer immunosurveillance and immunoediting processes has been primarily demonstrated in...
Cancer vaccines serve as a promising clinical immunotherapeutic strategy that help to trigger an eff...
Breast cancer recurrence is the primary cause of mortality in breast cancer, and although advances h...
Vaccines against human breast cancer are an unfulfilled promise. Despite decades of promising precl...
International audienceObjectives. To better understand how immune responses may be harnessed against...
ABSTRACTPredisposition to breast and extrauterine Müllerian carcinomas in BRCA1 mutation carriers is...
In recent years, immune manipulation for cancer treatment, including breast cancer, has been increas...